Glucagon-like Peptide-1 Receptor Agonists, Tirzepatide and Muscle-Related Body Composition: A Systematic Review and Meta-Analysis
Endocrines · 11.11.2026 · 7 (4) · 72
DOI: 10.3390/endocrines7040072 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrines, online erschienen am 11.11.2026. Verfasst von Benedetta Di Marzio und 9 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: GLP-1 receptor agonists (GLP-1RAs) and the dual GIP/GLP-1 receptor agonist tirzepatide reduce body weight, but their effects on muscle-related body-composition measures and physical function remain uncertain. We evaluated changes in skeletal muscle mass (SMM), lean mass, and related outcomes and performed a focused meta-analysis of compatible bioelectrical impedance analysis (BIA) cohorts.
Methods
PubMed, Embase, and the Cochrane Library were searched for studies published from 2009 through 30 April 2026. Eighteen unique studies reported in 19 publications were included. A post hoc quantitative synthesis pooled five BIA-derived cohorts from four studies in adults with type 2 diabetes using a random-effects model.
Results
Nineteen publications describing 18 unique studies (total n = 3541; age range 45.4–76.7 years) were included. The pooled within-group change across compatible BIA cohorts was −0.90 kg (95% CI −1.21 to −0.59; I2 = 57.3%). This estimate does not establish a causal drug effect. DXA and BIA outcomes were synthesized separately because they are not interchangeable.
Conclusions
GLP-1RA treatment was accompanied by a small within-group reduction in heterogeneous BIA-derived muscle-mass estimates, but the certainty of this evidence was very low. DXA-derived lean mass, BIA-derived muscle mass, and sarcopenia are not interchangeable outcomes. The available data do not establish a drug-specific loss of contractile muscle or functional decline. Standardized controlled studies incorporating muscle strength and physical performance are required.
Zitieren
APA
Marzio, B. D., Papa, M. V., Perencin, A., Iervolino, D., Ambrosio, A., Ceolin, C., Rui, M. D., Sergi, G., Gasparini, G., & Sartore, G. (2026). Glucagon-like Peptide-1 Receptor Agonists, Tirzepatide and Muscle-Related Body Composition: A Systematic Review and Meta-Analysis. Endocrines, 7(4), 72. https://doi.org/10.3390/endocrines7040072
Vancouver
Marzio BD, Papa MV, Perencin A, Iervolino D, Ambrosio A, Ceolin C, et al. Glucagon-like Peptide-1 Receptor Agonists, Tirzepatide and Muscle-Related Body Composition: A Systematic Review and Meta-Analysis. Endocrines. 2026;7(4):72. doi:10.3390/endocrines7040072
BibTeX
@article{Marzio2026,
author = {Marzio, Benedetta Di and Papa, Mario Virgilio and Perencin, Alessandro and Iervolino, Domenico and Ambrosio, Andrea and Ceolin, Chiara and Rui, Marina De and Sergi, Giuseppe and Gasparini, Giulia and Sartore, Giovanni},
title = {Glucagon-like Peptide-1 Receptor Agonists, Tirzepatide and Muscle-Related Body Composition: A Systematic Review and Meta-Analysis},
journal = {Endocrines},
year = {2026},
volume = {7},
number = {4},
pages = {72},
doi = {10.3390/endocrines7040072}
}
EUVIMED